TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11206638

Group type: EXPERIMENTAL
Intervention: Clarithromycin 100 mg (group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg (group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 15
Study: 9020563

Group type: EXPERIMENTAL
Intervention: Salivary alpha-amylase activity in serum
Number of subjects: 119

Group type: COMPARATOR
Intervention: Serum and urine of women with nonneoplastic diseases
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Alpha-amylase activity in serum
Number of subjects: 119
Study: 3703931

Group type: EXPERIMENTAL
Intervention: Isokinetic training on the Kinetron exercise machine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapeutic exercise program and gait training (Control)
Number of subjects: 20
Study: 30485674

Group type: EXPERIMENTAL
Intervention: Surveys in general surgery and colorectal surgery
Number of subjects: 0
Study: 29695590

Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg once daily for 1 week, followed by tailored levodopa and/or opicapone dose adjustments
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Switching from entacapone to opicapone
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Long-term use of opicapone
Number of subjects: 495

Group type: COMPARATOR
Intervention: Dyskinesia as an adverse event
Number of subjects: 495
Study: 26985797

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (Eylea) 2 mg every 4 weeks (2q4)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (Eylea) 2 mg every 8 weeks (2q8)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) 0.5 mg every 4 weeks (Rq4)
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Fluid status at week 12
Number of subjects: 1465
Study: 25392635

Group type: EXPERIMENTAL
Intervention: Clonidine infusion (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline solution (group III)
Number of subjects: 60
Study: 22990469

Group type: EXPERIMENTAL
Intervention: Maternal weight at ∼10 wk gestation
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Total body water (TBW) at ∼10 wk gestation
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Upper arm muscle area (UAMA) at ∼10 wk gestation
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Change in TBW from ∼10-20 wk
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Maternal weight change from ∼10-20 wk
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Gains in weight from 20 to 32 wk
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Gains in UAMA from 20 to 32 wk
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Gains in upper arm fat area (UAFA) from 20 to 32 wk
Number of subjects: 350
Study: 20188604

Group type: EXPERIMENTAL
Intervention: Penicillin G potassium troches (50 mg), applied 4 times per day for 4 days
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 258

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 258
Study: 17609907

Group type: EXPERIMENTAL
Intervention: Needling on conventional acupoints plus DU20
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Needling on conventional acupoints plus DU26
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Needling on conventional acupoints plus HT7
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Needling on all three acupoints (DU20, DU26, HT7)
Number of subjects: 50
Study: 16055616

Group type: EXPERIMENTAL
Intervention: Home based psychoeducational intervention delivered by a respiratory nurse specialist for 6 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study: 11870180

Group type: EXPERIMENTAL
Intervention: FAP (fluorouracil, interferon alpha-2b, and cisplatin)
Number of subjects: 172

Group type: COMPARATOR
Intervention: M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both FAP and M-VAC
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: FAP
Number of subjects: 172

Group type: COMPARATOR
Intervention: M-VAC
Number of subjects: 172
Study: 10219721

Group type: EXPERIMENTAL
Intervention: Tinnitus management training (information, relaxation training, therapeutic noise strategy)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Long-term low-level white noise (LTWN) stimulation
Number of subjects: 65
Study: 8557216

Group type: EXPERIMENTAL
Intervention: Terguride (TER) 2 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2365462

Group type: EXPERIMENTAL
Intervention: Pn12F-DT conjugates (higher-molecular-weight)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pn12F-DT conjugates (lower-molecular-weight)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Both Pn12F-DT conjugates
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pnu-Imune (control)
Number of subjects: 3
Study: 377155

Group type: EXPERIMENTAL
Intervention: Thiothixene (Navane)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trifluoperazine and chlorpromazine (control)
Number of subjects: 30
Study: 31272427

Group type: EXPERIMENTAL
Intervention: Event notifications only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event notifications plus a care transitions intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27807908

Group type: EXPERIMENTAL
Intervention: Home-based management (discharge after 2 days for home-based management with nurse visits and multi-disciplinary team visits)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home-based management
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inpatient care (standard care with a 5 to 6 day initial inpatient stay)
Number of subjects: 50
Study: 25201130

Group type: EXPERIMENTAL
Intervention: Belly dancing (RG)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard medical care (CG)
Number of subjects: 114
Study: 23403883

Group type: EXPERIMENTAL
Intervention: Daily dose (20 mg iron and 100 μg folic acid)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Daily dose doubled (40 mg iron and 200 μg folic acid)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Weekly dose (40 mg iron and 200 μg folic acid)
Number of subjects: 426
Study: 20963434

Group type: EXPERIMENTAL
Intervention: BG-12 (240 mg orally three times daily for 24 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: BG-12
Number of subjects: 56
Study: 19597913

Group type: EXPERIMENTAL
Intervention: diacerein
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 16714913

Group type: EXPERIMENTAL
Intervention: 7-week applied relaxation training sessions
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 110
Study: 14992663

Group type: EXPERIMENTAL
Intervention: Self-initiated discussions of substance use and increased anxiety during family interactions (African American patients)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High levels of odd thinking and parents' criticism (White patients)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Depression during interaction (White patients)
Number of subjects: 58
Study: 11161392

Group type: EXPERIMENTAL
Intervention: Third generation chemotherapy regimens
Number of subjects: 1982

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 1982
Study: 9237707

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 62
Study: 7957488

Group type: EXPERIMENTAL
Intervention: CCK8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G17
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loxiglumide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-prandial condition
Number of subjects: 0
Study: 2890546

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg immediately after dinner
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg 3 hours after dinner
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg immediately after dinner
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg 3 hours after dinner
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 30584220

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Eicosapentaenoic acid (EPA 1.8 g/day)
Number of subjects: 66
Study: 29126691

Group type: EXPERIMENTAL
Intervention: tranexamic acid 10mg/kg body weight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tranexamic acid 15mg/kg body weight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tranexamic acid 20mg/kg body weight
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 25668386

Group type: EXPERIMENTAL
Intervention: Home-based delivery of motivational interviewing plus skills building for 3 months
Number of subjects: 181

Group type: COMPARATOR
Intervention: Office-based delivery of motivational interviewing plus skills building for 3 months
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Continued home-based skills for nonresponders after 3 months
Number of subjects: 181

Group type: COMPARATOR
Intervention: Contingency management for nonresponders after 3 months
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Adolescent executive functioning
Number of subjects: 181
Study: 25452097

Group type: EXPERIMENTAL
Intervention: Combined music and aroma
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Music alone
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Aroma alone
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control
Number of subjects: 224
Study: 22289131

Group type: EXPERIMENTAL
Intervention: Drink refusal skills training (part of a 16-week combined behavioral intervention)
Number of subjects: 776
Study: 20574136

Group type: EXPERIMENTAL
Intervention: Bezafibrate (200-400 mg/day)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Pravastatin (10-20 mg/day)
Number of subjects: 274
Study: 17640111

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily
Number of subjects: 1514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily (in subgroup of very severe COPD)
Number of subjects: 1514

Group type: COMPARATOR
Intervention: Placebo (in subgroup of very severe COPD)
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily (in subgroup of high healthcare utilization)
Number of subjects: 1514

Group type: COMPARATOR
Intervention: Placebo (in subgroup of high healthcare utilization)
Number of subjects: 1514
Study: 16103242

Group type: EXPERIMENTAL
Intervention: Volumetric analysis technique using RT3DE images
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Automated detection of regional WM abnormalities
Number of subjects: 30
Study: 11815511

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 12
Study: 10412677

Group type: EXPERIMENTAL
Intervention: Cluster schedule
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Conventional schedule
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 63
Study: 7749804

Group type: EXPERIMENTAL
Intervention: Low-fat diet (24% fat)
Number of subjects: 103

Group type: COMPARATOR
Intervention: High-fat diet (46% fat)
Number of subjects: 103
Study: 2331203

Group type: EXPERIMENTAL
Intervention: Cholesterol screening with brief nonphysician counseling (3- to 5-minute counseling by a registered nurse)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Frequent follow-up (cholesterol measurement and brief counseling at 2, 4, and 6 months)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Follow-up at 6 months only
Number of subjects: 886
Study: 373260

Group type: EXPERIMENTAL
Intervention: Cimetidine 1000 mg daily for 4 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 91
Study: 31430404

Group type: EXPERIMENTAL
Intervention: LOW-CHO
Number of subjects: 13

Group type: COMPARATOR
Intervention: HIGH-CHO
Number of subjects: 13
Study: 28174194

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Sham RIPC
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study: 26193827

Group type: EXPERIMENTAL
Intervention: Nurse-led structured psychosocial intervention program (plus usual care)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual psychiatric outpatient care
Number of subjects: 180
Study: 23784892

Group type: EXPERIMENTAL
Intervention: four‐session lifestyle program
Number of subjects: 228
Study: 21130987

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 120
Study: 19299766

Group type: EXPERIMENTAL
Intervention: Air/Oxygen (FIO2 = 0.4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide/Oxygen (N2O, FIO2 = 0.4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxygen (O2, FIO2 = 1.0)
Number of subjects: 100
Study: 17855668

Group type: EXPERIMENTAL
Intervention: Dilute diesel exhaust (300 mug per cubic meter)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dilute diesel exhaust
Number of subjects: 20
Study: 15184734

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7601
Study: 11482588

Group type: EXPERIMENTAL
Intervention: Health Care Financing Administration's pilot Medicare & You 1999 handbook
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Medicare version of the Consumer Assessment of Health Plans (CAHPS) report
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Medicare & You bulletin, an abbreviated version of the handbook
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2000
Study: 9726084

Group type: EXPERIMENTAL
Intervention: Safer-sex education (individual teaching approach)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safer-sex education (interactive education methods)
Number of subjects: 0
Study: 7913703

Group type: EXPERIMENTAL
Intervention: p105 labeling index (LI-C)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: p105 labeling index of cells in S phase (LI-S)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: p105 antigen density (AD)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DNA ploidy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: T-stage
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: N-stage
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Primary site
Number of subjects: 143
Study: 2729315

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bendrofluazide + Albuterol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bendrofluazide + Albuterol (Women)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Albuterol alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 10
Study: 31164116

Group type: EXPERIMENTAL
Intervention: Experimental anhydrous 0.454% SnF2/polyphosphate toothpaste (Test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate toothpaste (Control)
Number of subjects: 0
Study: 29096915

Group type: COMPARATOR
Intervention: Provisional Stenting (PS), n = 242
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Double Kissing (DK) crush stenting, n = 240
Number of subjects: 482

Group type: COMPARATOR
Intervention: Provisional Stenting (PS)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Double Kissing (DK) crush stenting
Number of subjects: 482
Study: 26512046

Group type: EXPERIMENTAL
Intervention: Ramosetron, aprepitant, and dexamethasone (RAD)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Ondansetron, aprepitant, and dexamethasone (OAD)
Number of subjects: 299
Study: 23391465

Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 2797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2797
Study: 21256000

Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin plus 5‐fluorouracil (5‐FU) and intravenous ZOL (4 mg, q4 wks) for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy with cisplatin plus 5‐fluorouracil (5‐FU) alone
Number of subjects: 60
Study: 18067561

Group type: EXPERIMENTAL
Intervention: Initial thrombosuction (IT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Initial thrombosuction (IT) in subgroup 2 (241-480 min)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard PCI in subgroup 2 (241-480 min)
Number of subjects: 74
Study: 16564942

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (300 mg with each dialysis session)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care only (Control group)
Number of subjects: 46
Study: 12629463

Group type: COMPARATOR
Intervention: 3 weeks of bicycle ergometer training, 45 min of exercise at 70% VO(2)max, 3‐4 times a week
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3 weeks of bicycle ergometer training
Number of subjects: 12
Study: 11145380

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 50
Study: 8884050

Group type: EXPERIMENTAL
Intervention: Cigarette smokers with occupational exposure to organic solvents
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Non-smokers with occupational exposure to organic solvents
Number of subjects: 139

Group type: COMPARATOR
Intervention: Smokers not exposed to chemical compounds
Number of subjects: 139

Group type: COMPARATOR
Intervention: Non-smokers not exposed to chemical compounds
Number of subjects: 139
Study: 1733001

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other medications used commonly for secondary prophylaxis
Number of subjects: 0
Study: 6704282

Group type: EXPERIMENTAL
Intervention: Nifedipine (single sublingual dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31416472

Group type: EXPERIMENTAL
Intervention: Exercise in heat (30°C)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exercise in cold (-10°C)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exercise in temperate (21°C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Resting (sedentary) at 21°C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Post-treatment period (6h after treatment)
Number of subjects: 18
Study: 29960852

Group type: EXPERIMENTAL
Intervention: KetoCal® (4:1 ketogenic ratio formula), 8-ounce (237 mL) daily for the first month
Number of subjects: 80

Group type: COMPARATOR
Intervention: Modified Atkins Diet (MAD) alone
Number of subjects: 80
Study: 26682757

Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 498
Study: 25375851

Group type: EXPERIMENTAL
Intervention: Aspheric LASIK
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wavefront-guided LASIK
Number of subjects: 40
Study: 21465608

Group type: EXPERIMENTAL
Intervention: Conventional curvilinear transducer and MTI filtered color flow mapping
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High-frequency linear transducer
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MTI filtered color flow mapping
Number of subjects: 300
Study: 20188444

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard therapy (vancomycin 1g every 12h or antistaphylococcal penicillin 2g every 4h, both with gentamicin 1mg/kg every 8h for the first 4 days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 53
Study: 17659004

Group type: EXPERIMENTAL
Intervention: 250 mg oral Polypodium leucotomos three times daily with NB-UVB twice weekly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo with NB-UVB twice weekly
Number of subjects: 50
Study: 16195287

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 600 microg
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study: 12124820

Group type: EXPERIMENTAL
Intervention: CMFEV (cyclophosphamide, methotrexate, epirubicin, and vincristine)
Number of subjects: 211

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 211
Study: 11040233

Group type: EXPERIMENTAL
Intervention: Enalaprilat (ACE inhibitor)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dihydralazine (nonspecific vasodilator)
Number of subjects: 48
Study: 8615488

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 0.5 mg/kg intravenously
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1580727

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 1214
Study: 6146006

Group type: EXPERIMENTAL
Intervention: Oral acyclovir 200 mg four times a day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30640697

Group type: EXPERIMENTAL
Intervention: Intravenous oxaliplatin 75 mg/m2 on day 1 and intraperitoneal docetaxel 75 mg/m2 on day 2
Number of subjects: 12
Study: 30184035

Group type: EXPERIMENTAL
Intervention: High-Intensity Inspiratory Muscle Training (IMT) associated with aerobic exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aerobic exercise only (Control)
Number of subjects: 24
Study: 27812501

Group type: EXPERIMENTAL
Intervention: Verum acupuncture plus fluoxetine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham acupuncture plus fluoxetine
Number of subjects: 46
Study: 24647680

Group type: EXPERIMENTAL
Intervention: DECIDE intervention (three training sessions delivered by a care manager)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Control group (brochure on management of behavioral health)
Number of subjects: 647